
    
      This is a prospective, multicenter, open-label, single arm, observational evaluation of the
      corneal ECD change from baseline for subjects having the Retisert FA drug delivery system
      (0.59 mg) surgically implanted in the ocular vitreous chamber of at least 1 previously
      unimplanted eye for at least 1 year.
    
  